Inhibitors of MIF having a naphthyridine backbone are provided which have
utility in the treatment of a variety of disorders, including the
treatment of pathological conditions associated with MIF activity. The
inhibitors of MIF have the following structures: 1
including stereoisomers, prodrugs and pharmaceutically acceptable salts
thereof, wherein n, R, R.sub.1, R.sub.2, X, Y and Z are as defined
herein. Compositions containing an inhibitor of MIF in combination with a
pharmaceutically acceptable carrier are also provided, as well as methods
for use of the same.
